NL-OMON41276已完成4 期
Establish limits for fitness to drive with prolonged use of ICADTS class III medication - ICADTS III
Ministerie van Volkshuisvesting, Ruimtelijke Ordening en Milieu (VROM)0 个研究点目标入组 272 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 272
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients: chronic use of ICADTS class III medication (> 6 months)
- •- age between 21 and 75 (inclusive)
- •- BMI between 19 an 29 m2/kg (inclusive)
- •- in posession of a valid drivers license for at least 3 years
- •- driving experience of at least 3000 km/yeat on average
- •- sufficient vision
排除标准
- •- a neurological disorder
- •- use of drugs
- •- excessive alcohol consumption (> 21 glasses of alcohol/week)
- •- smoking (> 10 cigarettes/day)
研究者
相似试验
进行中（未招募）
1 期
ICADTS class III medication and fitness to driveEUCTR2013-004936-31-NLMinistry of Infrastructure and the Environment
招募中
不适用
A new clinical tool to assess fitness-to-drive in obstructive sleep apneaObstructive Sleep ApneaRespiratory - Sleep apnoeaACTRN12619001067167Flinders University100
尚未招募
不适用
An assessment of driving fitness in patients with visual field defect using driving simulatorglaucoma, retinitis pigmentosa, hemianopiaJPRN-UMIN000026794Division of Ophthalmology and Visual Science,Graduate School of Medical and Dental Sciences, Niigata University.200
已完成
2 期
Driving fitness under Silexan compared to placebo and lorazepamISRCTN32209377Dr. Willmar Schwabe GmbH & Co. KG201
进行中（未招募）
1 期
Influence of Silexan® on driving fitnessEUCTR2015-001101-14-DEDr. Willmar Schwabe GmbH & Co. KG72